"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
| Descriptor ID |
D017239
|
| MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
| Concept/Terms |
Taxol- Taxol
- Taxol A
- Bris Taxol
- Taxol, Bris
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 4 | 1 | 5 |
| 2004 | 1 | 1 | 2 |
| 2005 | 4 | 0 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 0 | 2 |
| 2009 | 5 | 2 | 7 |
| 2010 | 2 | 2 | 4 |
| 2011 | 0 | 2 | 2 |
| 2012 | 2 | 5 | 7 |
| 2013 | 0 | 3 | 3 |
| 2014 | 1 | 5 | 6 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 3 | 5 |
| 2018 | 2 | 1 | 3 |
| 2019 | 4 | 2 | 6 |
| 2020 | 3 | 5 | 8 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 3 | 4 |
| 2023 | 3 | 3 | 6 |
| 2024 | 2 | 2 | 4 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial. Mol Cancer. 2025 Mar 26; 24(1):96.
-
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2025 02 03; 8(2):e2461639.
-
Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024 Dec 01; 120(5):1332-1343.
-
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
-
Alleviating iatrogenic effects of paclitaxel via antiinflammatory treatment. Vasc Med. 2024 08; 29(4):369-380.
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 04; 25(4):488-500.
-
Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve. J Adolesc Young Adult Oncol. 2024 06; 13(3):465-468.
-
Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma. Cancer Res. 2023 10 02; 83(19):3184-3191.
-
Estrogen Receptor ?4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer. Int J Mol Sci. 2023 Mar 20; 24(6).
-
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023 04; 171:141-150.